Design and Baseline Characteristics of Phase 3, Double-Blind, Randomised Trials Evaluating the Efficacy and Safety of Evobrutinib Versus Teriflunomide in Relapsing Multiple Sclerosis (evolutionRMS 1 and 2)

Authors
Category Primary study
ConferenceMultiple Sclerosis and Related Disorders
Year 2023
This article has no abstract
Epistemonikos ID: 08ed62a84d9dad90d77f37a022893c2b5f9b7275
First added on: Apr 29, 2026